FOURward, NCT02175966: Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C ( Study) |
|
|
| Completed | 2 | 35 | US | DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir, Sovaldi®, Peginterferon α-2a | Bristol-Myers Squibb | Hepatitis C | 01/15 | 12/15 | | |
QUATTROTURBO, NCT02309450: Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen |
|
|
| Withdrawn | 2 | 0 | Europe | .Asunaprevir, Daclatasvir and BMS - 791325 | ANRS, Emerging Infectious Diseases, Bristol-Myers Squibb | Hepatitis C Virus Genotype 4 Infection | 11/15 | 08/16 | | |
